Support drugs

Jyseleca filgotinib) is a Janus kinase 1 (JAK1) inhibitor indicated for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Indications

Ulcerative colitis: treatment of exacerbations and prevention of relapses.

Crohn's disease: treatment of exacerbations.

Rheumatoid arthritis

 RINVOK® indications for the treatment of rheumatoid arthritis of moderate to high stage of activity in adult patients, if adequate evidence has not been eliminated or there is an underlying intolerance to one or several anti-rheumatic drugs drugs that modify disease progression (DMARDs – disease-modifying antirheumatic drugs).

 RINVOK® can be used as monotherapy or in combination with methotrexate.

 Psoriatic arthritis

 RINVOK® indications for the treatment of active psoriatic arthritis in adult patients in whom there is an inadequate response or intolerance to one or several anti-rheumatic drugs that modify the treatment sickness RINVOK® can be used as monotherapy or in combination with methotrexate.

 Axial spondyloarthritis

 Non-radiographic axial spondyloarthritis (nr-axial spondyloarthritis)

 RINVOK® indications for the treatment of active non-radiographic axial spondyloarthritis in adults with objective signs of inflammation, confirmed by an elevated level of C-reactive protein (CRP) and/or MRI data, and with inadequate I qualify for therapy with non-steroidal anti-inflammatory drugs (NSAIDs).

 Ankylosing spondylitis (AS, radiographic axial spondylitis)

 RINVOK® indications for the treatment of active ankylosing spondylitis in adult patients with inadequate response to standard therapy.

 Atopic dermatitis

 RINVOK® is indicated for the treatment of moderate to severe atopic dermatitis in adults and children over 12 years of age, which are candidates for systemic therapy.

 Virascovian colitis

 RINVOK® indications for the treatment of viral colitis of mild or pronounced activity in adult patients with inadequate subtype, waste type or intolerance to standard therapy or biological drugs.

 Crohn's disease

 RINVOK® indications for the treatment of moderate to severe Crohn's disease in adult patients with inadequate response, loss of response or intolerance to standard therapy

 or biological drugs.

OCALIVA is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA.

Лікування дорослих пацієнтів із ревматоїдним артритом, що характеризується середнім та тяжким ступенем активності, за наявності непереносимості або недостатньої відповіді на метотрексат.

Лікування активного поліартикулярного ювенільного ідіопатичного артриту (ЮІА) у дорослих та пацієнтів дитячого віку з масою тіла більше 40 кг.